Loading…
Chinese molecular and rapid-diagnostics maker selling PCR and antigen test kits for infectious diseases.
Chinese molecular and rapid-diagnostics maker selling PCR and antigen test kits for infectious diseases.
Sells test kits and the instruments that run them, so each installed analyser brings repeat kit orders. Covid testing lifted sales sharply in the early 2020s, and the business has since returned to routine infectious-disease testing and export orders.
In one line: A Chinese Cepheid/Abbott Rapid Diagnostics for infectious-disease tests.
Moat: narrow (regulatory licence, installed base). Disease-testing registrations and installed instrument base favor an incumbent supplier.
Headquarters: Beijing, China · Employees: 946
Size Beijing Hotgen Biotech (688068.SS) is a China Health Care company (Medical Specialties) with a market value of $966M, the 2359th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥69.41 on 6 Nov 2026.
Performance Over six months the shares fell 38.1%, against -18.7% for the median peer and -16.4% for the China market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue grew 8.2% over the last twelve months (peer median +5.4%); the operating margin is -94.3% (peer median 10.9%).
Valuation It trades at 11.7× enterprise value to sales against a peer median of 3.5× (3rd most expensive of 21).
Capital Return on invested capital runs 27.0 points below its cost of capital (8.8% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥470M | CN¥404M | CN¥508M | CN¥546M | CN¥3.55B |
| Revenue growth | — | -20% | -7% | -85% | — |
| Gross profit | CN¥311M | CN¥157M | CN¥193M | CN¥262M | CN¥1.84B |
| EBITDA | n/a | -CN¥189M | -CN¥111M | CN¥25.6M | CN¥1.25B |
| Net income | -CN¥316M | -CN¥216M | -CN¥206M | CN¥28.9M | CN¥945M |
| Free cash flow | -CN¥339M | -CN¥92.8M | -CN¥104M | -CN¥435M | CN¥431M |
| Capital expenditure | CN¥111M | CN¥43.6M | CN¥52.8M | CN¥413M | CN¥565M |
| Total debt | CN¥28.6M | CN¥75.7M | CN¥85.4M | CN¥16.1M | CN¥42.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Beijing Hotgen Biotech 688068.SS | $966M | -38% | +8% | -94% | 11.7× | n/a |
| Sansure Biotech 688289.SS | $1.36B | -8% | -1% | 1% | 4.3× | n/a |
| Danaher DHR | $162B | +35% | +6% | 21% | 7.2× | 20.5% |
| Abbott Laboratories ABT | $190B | +30% | +10% | 14% | 3.9× | 5.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688068.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -18.8% | -2.6% | 4th lowest of 21 |
| 6-month return | -38.1% | -18.7% | lowest of 21 |
| Distance from 52-week high | -67.7% | -34.7% | lowest of 21 |
| Revenue growth (TTM) | +8.2% | +5.4% | 10th highest of 21 |
| Operating margin | -94.3% | 10.9% | lowest of 21 |
| EV / Sales | 11.7× | 3.5× | 3rd most expensive of 21 |
| ROIC minus cost of capital | -27.0 pp | +1.1 pp | lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beijing Hotgen Biotech 688068.SS | China | $966M | -38% | +8% | -94% | 11.7× | n/a | n/a |
| Eckert & Ziegler EUZ.DE | Germany | $969M | -7% | +4% | 25% | 2.5× | 7.2% | +12.1% |
| Xiangyu Medical 688626.SS | China | $969M | -31% | 0% | 4% | 8.0× | n/a | n/a |
| HOB Biotech 688656.SS | China | $972M | -22% | +6% | 7% | 15.6× | 40.1% | +12.4% |
| Kuros Biosciences KURN.SW | Switzerland | $953M | +3% | +41% | 6% | 5.6× | n/a | n/a |
| Shenzhen YHLO Biotech 688575.SS | China | $950M | -20% | +3% | 12% | 3.4× | 3.1% | +12.7% |
| Artivion AORT | United States | $985M | -20% | +16% | 7% | 2.8× | n/a | n/a |
| Shantou Institute of Ultrasonic Instruments 301602.SZ | China | $944M | -19% | +4% | 30% | 13.5× | 13.1% | +4.6% |
| Castle Biosciences CSTL | United States | $993M | +64% | +3% | -9% | 2.1× | n/a | n/a |
| Caina Technology 301122.SZ | China | $938M | +60% | +61% | 0% | 10.3× | n/a | n/a |
| Aidite (Qinhuangdao) Technology 301580.SZ | China | $919M | -20% | +17% | 18% | 4.2× | 19.9% | +23.3% |
| Seegene 096530.KS | South Korea | $915M | +26% | +12% | 13% | 1.6× | -3.4% | -15.9% |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $915M | -30% | +36% | 14% | 9.6× | 47.2% | +17.1% |
| LifeTech Scientific 1302.HK | Hong Kong | $914M | -18% | +1% | 12% | 4.0× | 13.3% | +15.5% |
| Beijing SDL Technology 002658.SZ | China | $910M | -21% | -13% | 9% | 3.5× | 18.0% | +2.9% |
| Shanghai Runda Medical Technology 603108.SS | China | $909M | -25% | -12% | -2% | 1.9× | 22.2% | -0.2% |
| Mani 7730.T | Japan | $909M | -15% | +10% | 30% | 3.5× | 1.5% | +13.9% |
| Ceribell CBLL | United States | $1.03B | +32% | +31% | -70% | 8.6× | n/a | n/a |
| Bioventus BVS | United States | $894M | +1% | +4% | 10% | 2.0× | 6.9% | +12.1% |
| Integra LifeSciences IART | United States | $1.04B | -4% | +1% | 12% | 1.6× | 5.2% | +3.6% |
| Edan Instruments 300206.SZ | China | $1.05B | -19% | +14% | 17% | 2.7× | 7.7% | -2.9% |